Association between etanercept use and employment outcomes among patients with rheumatoid arthritis.
about
Non-pharmacological interventions for preventing job loss in workers with inflammatory arthritisNon-pharmacological interventions for improving work participation in patients with inflammatory arthritisWork disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA studyWork dynamics among persons with systemic lupus erythematosusWorking status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.Predictive factors of work disability in rheumatoid arthritis: a systematic literature reviewHealth economics: implications for novel antirheumatic therapies.Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US.Work disability among two cohorts of women with recent-onset rheumatoid arthritis: a survival analysisSick leave and work disability in patients with early arthritisSystematic review of studies of productivity loss due to rheumatoid arthritis.Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out.Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.The impact of rheumatoid arthritis and biologics on employers and payers.The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of lifeA pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis.Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register.Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.Biotech injectable drugs: clinical applications and financial effects.Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis.Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden.Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA.Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohort.The effect of rheumatoid arthritis on personal income in Australia.Work instability in rheumatoid arthritis patients from Argentina: prevalence and associated factors.Cost of Finnish statutory inpatient rehabilitation and its impact on functional and work capacity of patients with early rheumatoid arthritis: experience from the FIN-RACo trial.Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients.A two‐year follow‐up of work capacity in early rheumatoid arthritis: a study of multidisciplinary team care with emphasis on vocational supportThe economic burden of rheumatoid arthritis: beyond health care costsThe effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study
P2860
Q24188097-4CCF5172-D3EB-4385-8E11-8984CE214F7CQ24197632-CA218B0B-11EB-450A-B979-81C17CFE4FB9Q33540305-A24EDD13-2995-49F2-B386-55C1B4EE4612Q33871651-9CE73B18-842C-4526-8A97-42E6223E09B6Q33990812-73C7D27E-9563-486E-892F-6E4C7578D1F2Q35553588-8D1639C9-EDDF-4DE0-8A3E-0F96CE824F47Q35579507-CE9469FC-1B69-43B9-AFF8-B27ED1FC2107Q35638583-D85BE4CB-E7E3-4801-AA35-70873F8B8D2CQ35754388-E64DF165-D279-4E6A-A662-2F4315C3AA4DQ36166120-BE91345E-9A14-42DD-9FD6-2963A571B724Q36312507-9B22E0A9-3F45-498E-8D00-4D3D0D0B2D43Q36843031-4A235A05-FB6A-4BF8-9EB9-694118211EF7Q37172804-F345D15B-3A1C-43D2-8417-D247EEB19CADQ37251489-1D7331F9-2BE9-455B-BED5-38E48AB54619Q37358093-AE699958-186F-49B1-9D03-66B148035293Q37609399-B9A682E1-2805-4329-A75C-91A61BDA2BDFQ38689012-D946EA88-102F-4A57-92A0-54FE41A80347Q40360229-163C6C53-FD1A-49B7-9A00-91E794F8AC01Q40455661-C3B3EAA9-3015-4830-9DED-B47CA8576F16Q42277544-EAF4AE4B-D936-4C6E-8F44-6C2AC76EB688Q44373707-A649E1C0-69AD-4FB0-ADC6-3DB1890BBE96Q44918475-388742C9-F37F-41C8-8FCB-5A3E334D2480Q45190511-84B78E05-1BD5-41EB-9417-5BE26C8C73D0Q45769410-034DA28B-5FB7-4DF6-91FC-6624D0BF2D73Q51110263-6A11FFEE-5507-4676-B891-2C1086ABBFA9Q51132948-77F996C9-0E31-4D59-B655-E91AC917C6F3Q51906908-8F3A3A6E-70FF-4473-A7BC-9256229F7A25Q55098455-4AE4DEE8-2A1E-4754-A706-C55C2746C310Q57349848-DA286018-7255-478A-9232-77143447B571Q58025187-C5583300-21A2-46A0-99A8-89C675F04934Q58025221-8496AB8B-C1C3-46C0-A894-8240D13BE772
P2860
Association between etanercept use and employment outcomes among patients with rheumatoid arthritis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Association between etanercept ...... nts with rheumatoid arthritis.
@en
Association between etanercept ...... nts with rheumatoid arthritis.
@nl
type
label
Association between etanercept ...... nts with rheumatoid arthritis.
@en
Association between etanercept ...... nts with rheumatoid arthritis.
@nl
prefLabel
Association between etanercept ...... nts with rheumatoid arthritis.
@en
Association between etanercept ...... nts with rheumatoid arthritis.
@nl
P2093
P356
P1476
Association between etanercept ...... nts with rheumatoid arthritis.
@en
P2093
Deborah Lubeck
Edward Yelin
Laura Trupin
Patricia Katz
Stephanie Rush
P304
P356
10.1002/ART.11285
P577
2003-11-01T00:00:00Z